[go: up one dir, main page]

WO2006035432A3 - Silençage genique s'utilisant en dermatologie - Google Patents

Silençage genique s'utilisant en dermatologie Download PDF

Info

Publication number
WO2006035432A3
WO2006035432A3 PCT/IL2005/001031 IL2005001031W WO2006035432A3 WO 2006035432 A3 WO2006035432 A3 WO 2006035432A3 IL 2005001031 W IL2005001031 W IL 2005001031W WO 2006035432 A3 WO2006035432 A3 WO 2006035432A3
Authority
WO
WIPO (PCT)
Prior art keywords
present
cells
treating
duplexes
sirna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2005/001031
Other languages
English (en)
Other versions
WO2006035432A2 (fr
Inventor
Emanuel A Yakobson
Yechezkel Sidi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ERVICES Ltd TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND S
ERVICES Ltd TEL HASHOMER MEDIC
Original Assignee
ERVICES Ltd TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND S
ERVICES Ltd TEL HASHOMER MEDIC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ERVICES Ltd TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND S, ERVICES Ltd TEL HASHOMER MEDIC filed Critical ERVICES Ltd TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND S
Publication of WO2006035432A2 publication Critical patent/WO2006035432A2/fr
Publication of WO2006035432A3 publication Critical patent/WO2006035432A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/02—Pentosyltransferases (2.4.2)
    • C12Y204/0203—NAD+ ADP-ribosyltransferase (2.4.2.30), i.e. tankyrase or poly(ADP-ribose) polymerase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention est basée sur des résultats empiriques démontrant que, lorsqu'on combine des doubles hélices d'ARN (ARNsi) d'interférence courtes (petites) avec des réactifs de transfection à base de lipides et lorsqu'on les incube avec des cellules de la peau telles que les kératinocytes et des cellules de mélanome, on parvient à une inhibition importante de la prolifération des cellules. L'invention porte également sur l'utilisation des doubles hélices d'ARNsi comprenant des séquences complémentaires sens et antisens sur au moins une partie d'une séquence d'ARNm, ou sur une forme d'épissure alternative, un mutant ou un parent de celle-ci, dans la préparation d'une composition pharmaceutique pour traiter une maladie ou état dermatologique. L'invention porte également sur des méthodes thérapeutiques et sur des compositions pharmaceutiques destinées à traiter les maladies et états dermatologiques.
PCT/IL2005/001031 2004-09-27 2005-09-27 Silençage genique s'utilisant en dermatologie Ceased WO2006035432A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61278304P 2004-09-27 2004-09-27
US60/612,783 2004-09-27

Publications (2)

Publication Number Publication Date
WO2006035432A2 WO2006035432A2 (fr) 2006-04-06
WO2006035432A3 true WO2006035432A3 (fr) 2006-06-01

Family

ID=35645872

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2005/001031 Ceased WO2006035432A2 (fr) 2004-09-27 2005-09-27 Silençage genique s'utilisant en dermatologie

Country Status (1)

Country Link
WO (1) WO2006035432A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110882219B (zh) * 2019-12-24 2021-04-20 厦门大学 一种siRNA经皮递送组合物及其用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070969A2 (fr) * 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. Inhibition de l'expression du gene bcl2 induite par interference arn au moyen de petits acides nucleiques interferents (sina)
US20040001811A1 (en) * 2001-01-09 2004-01-01 Ribopharma Ag Compositions and methods for inhibiting expression of anti-apoptotic genes
US20040082534A1 (en) * 2002-08-21 2004-04-29 Martin Gleave Treatment of melanoma by reduction in clusterin levels
US20040096882A1 (en) * 2002-08-21 2004-05-20 Martin Gleave RNAi probes targeting cancer-related proteins
WO2004046354A1 (fr) * 2002-11-20 2004-06-03 Beiersdorf Ag Oligoribonucleotides pour le traitement de maladies degeneratives de la peau par l'intermediaire de l'interference arn
WO2004083240A2 (fr) * 2003-03-18 2004-09-30 Jo Milner Regulation de l'expression de genes

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040001811A1 (en) * 2001-01-09 2004-01-01 Ribopharma Ag Compositions and methods for inhibiting expression of anti-apoptotic genes
WO2003070969A2 (fr) * 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. Inhibition de l'expression du gene bcl2 induite par interference arn au moyen de petits acides nucleiques interferents (sina)
US20040082534A1 (en) * 2002-08-21 2004-04-29 Martin Gleave Treatment of melanoma by reduction in clusterin levels
US20040096882A1 (en) * 2002-08-21 2004-05-20 Martin Gleave RNAi probes targeting cancer-related proteins
WO2004046354A1 (fr) * 2002-11-20 2004-06-03 Beiersdorf Ag Oligoribonucleotides pour le traitement de maladies degeneratives de la peau par l'intermediaire de l'interference arn
WO2004083240A2 (fr) * 2003-03-18 2004-09-30 Jo Milner Regulation de l'expression de genes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WACHECK V ET AL: "SMALL INTERFERING RNA TARGETING BCL-2 SENSITIZES MALIGNANT MELANOMA", ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, MARY ANN LIEBERT, INC., NEW YORK, US, vol. 13, no. 5, 2003, pages 393 - 400, XP001189796, ISSN: 1087-2906 *

Also Published As

Publication number Publication date
WO2006035432A2 (fr) 2006-04-06

Similar Documents

Publication Publication Date Title
Sunahori et al. The catalytic subunit of protein phosphatase 2A (PP2Ac) promotes DNA hypomethylation by suppressing the phosphorylated mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) kinase (MEK)/phosphorylated ERK/DNMT1 protein pathway in T-cells from controls and systemic lupus erythematosus patients
US8759308B2 (en) RNAi probes targeting cancer-related proteins
KR101857707B1 (ko) 아포지질단백질 c-iii 발현을 조절하는 조성물 및 방법
Wang et al. Bioengineering novel chimeric microRNA-34a for prodrug cancer therapy: high-yield expression and purification, and structural and functional characterization
JP6492053B2 (ja) 修飾ｔｇｆ−ベータオリゴヌクレオチド
US11578107B2 (en) Compositions and methods for reprogramming somatic cells into induced vasculogenic cells
CN103476947A (zh) 寡聚体的增强的生物分布
HK1211316A1 (en) Mirna modulators of thermogenesis
US12281310B2 (en) Use of trinucleotide repeat RNAs to treat cancer
WO2007112754A3 (fr) Composition pharmaceutique
CN102712925A (zh) 通过抑制sirtuin(sirt)的天然反义转录物来治疗sirtuin(sirt)相关性疾病
KR20180026778A (ko) 멜라닌 생성을 억제하는 rna 복합체
Zhou et al. MicroRNA-519d inhibits proliferation and induces apoptosis of human hypertrophic scar fibroblasts through targeting Sirtuin 7
WO2001084148A3 (fr) Pharmacogenomique et identification de cibles medicamenteuses par reconstruction des voies de transduction du signal a partir de sequences des regions accessibles
Li The role of MicroRNAs in vitiligo: Regulators and therapeutic targets
WO2006035432A3 (fr) Silençage genique s'utilisant en dermatologie
WO2005067632A3 (fr) Compositions lipidiques et leurs utilisations
US20170175112A1 (en) Mir-21-3p inhibitors in skin disorders
EP1598421A3 (fr) Oligoribonucleotides pour influencer la pousse des cheveux
TWI832851B (zh) 基質金屬蛋白酶-1之反義寡核苷酸
Sukma et al. The mRNA expression differences of RNA editing enzymes in differentiated and undifferentiated NG108-15 cells
Chang et al. 052 Keratin 17 Cre-driven deletion of Ncstn mice manifested phenotypes similar to human hidradenitis suppurativa
EP3171879B1 (fr) Prévention et traitement des maladies inflammatoires cutanées
TW201102091A (en) Compositions and methods for inhibiting expression of glucocorticoid receptor (GCR) genes
HK1240621A1 (en) Mirna modulators of thermogenesis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase